-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160

Benzinga·11/04/2026 12:15:15
Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $155 to $160.